CHMP konkluderede, at fordelene ved Daronrix opvejer risiciene, og at den er bevist at være velegnet som modelvaccine til forberedelse mod udbrud af en influenzapandemi.
The CHMP concluded that Daronrix’ s benefits outweighed its risks, and that it had shown its suitability as a mock-up vaccine in preparation for a pandemic flu outbreak.